This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care.
It does not cover gabapentinoids prescribed for epilepsy, nor opioids prescribed for acute or cancer pain, or at th...
This guideline covers interventions in secondary and further education to prevent and reduce
alcohol use among children and young people aged 11 up to and including 18. It also covers people
aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be
relevant to c...
Objetivos: El objetivo principal de esta Guía es recoger recomendaciones concretas basadas en los resultados de la literatura científica para tratar a pacientes con un trastorno mental grave y un consumo de sustancias atendidos en centros de tratamiento hospitalarios y ambulatorios. Incluye: 1) Recomen...
Mental Disorders/drug therapy,
Substance-Related Disorders/drug therapy,
Psychoanalytic Therapy,
Antidepressive Agents/therapeutic use,
Antipsychotic Agents/therapeutic use,
Clozapine/therapeutic use,
Dopamine Agonists/therapeutic use,
Naltrexone/therapeutic use,
Bupropion/therapeutic use,
Varenicline/therapeutic use,
Selective Serotonin Reuptake Inhibitors/therapeutic use,
Desipramine/therapeutic use,
Disulfiram/therapeutic use,
Buspirone/therapeutic use
La guía busca contestar las siguientes preguntas clínicas elaborando recomendaciones basadas en evidencia, En pacientes mayores de 18 años con abuso o dependencia del alcohol, ¿cuáles son los criterios clínicos más importantes para predecir el desarrollo de un síndrome de abstinencia? En paciente...
mhGAP is WHO’s action plan to scale up services for mental, neurological and substance use disorders for countries especially with low and lower middle incomes. The priority conditions addressed by mhGAP are: depression, schizophrenia and other psychotic disorders, suicide, epilepsy, dementia, disorder...